Covetrus Inc
F:2NJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (0.1), the stock would be worth €20.67 (4% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.1 | €21.52 |
0%
|
| 3-Year Average | 0.1 | €20.67 |
-4%
|
| 5-Year Average | 0.1 | €20.45 |
-5%
|
| Industry Average | 3.1 | €926.36 |
+4 205%
|
| Country Average | 2.5 | €745.94 |
+3 366%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
C
|
Covetrus Inc
F:2NJ
|
3B EUR | 0.1 | 1.4 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
101.9B USD | -78.5 | 23.5 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.9B USD | 31.5 | 36.9 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.4B USD | 31.1 | 36.6 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
47.2B USD | -16.4 | 28.4 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.1B AUD | 6.6 | 35.3 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
62.9B CNY | 0.8 | 11 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9B USD | 2.8 | 22.6 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
59.8B CNY | 2.5 | 21.1 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 6 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
61B HKD | 0.6 | 7.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Covetrus Inc
Glance View
Nestled in the heart of the animal health industry, Covetrus Inc. emerged as a formidable force, blending technological expertise with deep-rooted veterinary knowledge. Created in 2019 through the merger of Henry Schein Animal Health and Vets First Choice, this company has swiftly positioned itself as an essential partner for veterinary practitioners. Covetrus provides a comprehensive suite of services designed to streamline operations for veterinary clinics, ranging from practice management software to inventory management systems. The core of their operation focuses on enhancing clinic efficiency and improving patient outcomes, driven by digital innovation that connects clinics effortlessly with critical pharmaceuticals, pet foods, and other essential products. Covetrus's business model thrives on a multi-pronged approach. Revenue streams flow widely from the robust sales of prescription and non-prescription medications, medical supplies, and pet products, underpinned by its vast, integrated distribution network. Moreover, the company's software solutions, which are integral to their service offering, generate additional income through subscription fees and service upgrades. This ability to cross-sell digital and physical products creates a cohesive ecosystem for veterinary professionals, ensuring that Covetrus not only meets day-to-day operational needs but also facilitates long-term growth and competitiveness for its customers. Their strategic positioning within the veterinary supply chain, coupled with a clear focus on enhancing clinical workflows, cements Covetrus's role as an indispensable ally in modern animal healthcare.